A Sodium Glucose Cotransporter-2 Inhibitor Prevents the Progression of Macrophage-driven Atherosclerosis Dependent on Glyceamic Control in Diabetic Apolipoprotein E-null Mice

被引：0
|
作者：
Terasaki, Michishige
Hiromura, Munenori
Kohashi, Kyoko
Kushima, Hideki
Nagashima, Masaharu
Mori, Yusaku
Hirano, Tsutomu
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
522-P
引用
收藏
页码：A134 / A135
页数：2
相关论文
共 18 条
  • [11] Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
    Terasaki, Michishige
    Hiromura, Munenori
    Mori, Yusaku
    Kohashi, Kyoko
    Kushima, Hideki
    Ohara, Makoto
    Watanabe, Takuya
    Andersson, Olov
    Hirano, Tsutomu
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2017, 2017
  • [12] The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice
    Hanaguri, Junya
    Yokota, Harumasa
    Kushiyama, Akifumi
    Kushiyama, Sakura
    Watanabe, Masahisa
    Yamagami, Satoru
    Nagaoka, Taiji
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [13] Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice
    Suzuki, Masayuki
    Honda, Kiyofumi
    Fukazawa, Masanori
    Ozawa, Kazuharu
    Hagita, Hitoshi
    Kawai, Takahiro
    Takeda, Minako
    Yata, Tatsuo
    Kawai, Mio
    Fukuzawa, Taku
    Kobayashi, Takamitsu
    Sato, Tsutomu
    Kawabe, Yoshiki
    Ikeda, Sachiya
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 341 (03): : 692 - 701
  • [14] SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITION REDUCES ANGIOTENSIN-II INDUCED ABDOMINAL AORTIC ANEURYSM IN APOLIPOPROTEIN E-KNOCKOUT MICE
    Ortega, R.
    Collado, A.
    Selles, F.
    Real, J. T.
    Sanz, M. J.
    Piqueras, L.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 46 - 46
  • [15] The Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Empagliflozin Improves Insulin Sensitivity in db/db Mice in a Dose-Dependent Manner
    Kern, Matthias
    Kloeting, Nora
    Mayoux, Eric
    Mark, Michael
    Klein, Thomas
    Blueher, Matthias
    DIABETES, 2012, 61 : A262 - A263
  • [16] Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
    Ozutsumi, Takahiro
    Namisaki, Tadashi
    Shimozato, Naotaka
    Kaji, Kosuke
    Tsuji, Yuki
    Kaya, Daisuke
    Fujinaga, Yukihisa
    Furukawa, Masanori
    Nakanishi, Keisuke
    Sato, Shinya
    Sawada, Yasuhiko
    Saikawa, Soichiro
    Kitagawa, Koh
    Takaya, Hiroaki
    Kawaratani, Hideto
    Kitade, Mitsuteru
    Moriya, Kei
    Noguchi, Ryuichi
    Akahane, Takemi
    Mitoro, Akira
    Yoshiji, Hitoshi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (06)
  • [17] Glycemic control with canagliflozin, a SGLT-2 inhibitor, attenuates atherosclerosis and endothelial dysfunction in diabetic apolipoprotein e-deficient mice
    Rahadian, A.
    Fukuda, D.
    Salim, H.
    Yagi, S.
    Kusunose, K.
    Yamada, H.
    Soeki, T.
    Sata, M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 329 - 329
  • [18] Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice
    Takubo, Masahiro
    Watanabe, Kentaro
    Saito, Hitoki
    Kohno, Genta
    Ishihara, Hisamitsu
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2024,
12